Table 3 Risk of cancer diagnosis after stroke without and with consideration of death as competing risk in multivariable analyses.

From: A risk model for prediction of diagnosis of cancer after ischemic stroke

 

Risk of cancer diagnosis within 1 year after stroke

Data for 651 patients with all covariables available

Risk of cancer diagnosis within 3 years after stroke

Data for 651 patients with all covariables available

Hazard ratio (95% CI)

p value

Subdistribution hazard ratio (95% CI)

p value

Hazard ratio (95% CI)

p value

Subdistribution hazard ratio (95% CI)

p value

Sex

Male versus female (ref)

1.94 (0.72–5.19)

0.19

2.0 (0.67–5.99)

0.22

1.24 (0.60–2.62)

0.56

1.28 (0.56–2.93)

0.56

Age

1.04 (1.0–1.09)

0.07

1.03 (0.99–1.08)

0.11

1.04 (1.00–1.07)

*0.026

1.03 (1.0–1.05)

0.07

White blood cell count

 > 9,600/µl versus ≤ 9,600/µl (ref)

3.96 (1.46–10.77)

*0.007

3.68 (1.30–10.40)

*0.014

2.56 (1.21–5.41)

*0.044

2.45 (1.18–5.07)

*0.016

Platelet count

 > 400,000/µl versus ≤ 400,000/µl (ref)

7.86 (2.28–27.10)

*0.001

7.71 (2.44–24.41)

*0.001

4.11 (1.36–12.39)

*0.012

3.95 (1.39–11.27)

*0.01

Hemoglobin

 < 117 g/l (for women) and < 134 g/l (for men) versus > 117 g/l (for women) and for > 134 g/l (men) (ref)

1.57 (0.59–4.12)

0.36

1.47 (0.56–3.85)

0.43

1.49 (0.67–3.34)

0.33

1.29 (0.59–2.82)

0.53

Lactate dehydrogenase

 > 480 U/l versus ≤ 480 U/l (ref)

1.42 (0.52–3.89)

0.39

1.63 (0.64–4.19)

0.31

1.18 (0.52–2.71)

0.69

1.28 (0.54–3.03)

0.57

D-dimers

 ≥ 3 mg/l versus < 3 mg/l (ref)

4.40 (1.48–13.13)

*0.008

3.67 (1.42–9.50)

*0.007

2.54 (1.05–6.17)

*0.039

2.13 (0.97–4.68)

0.06

Venous thromboembolism prior to stroke

Yes versus no (ref)

2.46 (0.78–8.36)

0.12

2.78 (0.99–7.82)

0.05

1.59 (0.53–4.75)

0.40

1.76 (0.61–5.05)

0.30

Ischemic lesions in ≥ 2 vascular territories not attributed to cardioembolic etiology (TOAST 2)

Yes versus no (ref)

2.70 (0.81–8.98)

0.10

2.51 (0.79–7.98)

0.12

1.63 (0.55–4.86)

0.38

1.51 (0.51–4.48)

0.46